Showing results (851-860 of 922) with videos related to

Sort By:
Pageof 93
Blood|November 4, 2006
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemiaJeffrey E Lancet, Ivana Gojo, Jason Gotlib, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2005
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemiaEric J Feldman, Joseph Brandwein, Richard Stone, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|September 18, 2009
Usefulness and clinical impact of a fractional flow reserve and angiographic targeted strategy for coronary artery stenting: FROST III, a multicenter prospective registryP Dupouy, M Gilard, J-F Morelle, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1996
Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profileJ H Kehne, B M Baron, A A Carr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3Thomas Fischer, Richard M Stone, Daniel J Deangelo, et al.
Blood|December 28, 2007
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemiaMitch Raponi, Jeffrey E Lancet, Hongtao Fan, et al.
Human Molecular Genetics|September 25, 1997
A novel phenotypic pattern in X-linked inheritance: craniofrontonasal syndrome maps to Xp22G J Feldman, D E Ward, E Lajeunie-Renier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2004
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial resultsJohn P Leonard, Morton Coleman, Jamie C Ketas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2008
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapiesP Martin, A Chadburn, P Christos, et al.
Implant Dentistry|March 3, 2012
Use of cone beam computed tomography in implant dentistry: the International Congress of Oral Implantologists consensus reportErika Benavides, Hector F Rios, Scott D Ganz, et al.
Pageof 93